Leuven Lives up to KBI's High Quality Expectations
The KBI Biopharma analytical facility in Leuven, Belgium, has received a successful inspection from Belgium’s regulatory authority, the Federal...
News (3)
Tim Lowery Appointed Interim CEO of KBI and Selexis
Durham, North Carolina (November 09, 2022) -- KBI Biopharma & Selexis (“KBI”) today announced the appointment of JSR Life Sciences President Tim...
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
KBI and Selexis welcome Abdelaziz Toumi, Ph.D., as Chief Business Officer. Toumi will lead Global Business Development for KBI and Selexis as well as...
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel...
KBI Biopharma SA and Selexis SA Expand in Europe by Opening an Integrated Biologics Manufacturing Facility in Geneva, Switzerland
GENEVA, June 14, 2022— KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated...
KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility
EXPANDS US-BASED MAMMALIAN CELL CULTURE OPERATIONS
Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
KBI TO PRODUCE MATERIAL FOR USE IN FUTURE EXPECTED PHASE 2 CLINICAL TRIAL OF ORAGENICS’ INTRANASAL VACCINE CANDIDATE
KBI Biopharma Completes Eurofins DiscoverX Products Specialized Bioassay Certification Program
KBI BIOPHARMA COMPLETES EUROFINS DISCOVERX PRODUCTS SPECIALIZED BIOASSAY CERTIFICATION PROGRAM Companies will work together on critical components...
Adalta Secures AD-214 Resupply Under KBI Biopharma MSA
Adalta Secures AD-214 Resupply Under KBI Biopharma MSA
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND
SELEXIS AND KBI BIOPHARMA ENTER INTO AGREEMENTS WITH IMMATICS FOR INTEGRATED APPROACH TO ADVANCE IMMATICS TCR BISPECIFIC PROGRAM TOWARDS IND